COLO 678Homo sapiens (Human)Cancer cell line

Also known as: Colorado 678, COLO678, COLO #678, COLO-678, Colo-678

🤖 AI SummaryBased on 14 publications

Quick Overview

Human colorectal cancer cell line with known molecular characteristics.

Detailed Summary

COLO 678 is a human colorectal cancer cell line derived from a primary tumor. It is widely used in cancer research to study molecular mechanisms and drug responses. The cell line exhibits specific genetic and molecular features that make it a valuable model for understanding colorectal cancer biology. Research on COLO 678 has contributed to the identification of key pathways and potential therapeutic targets in colorectal cancer.

Research Applications

Molecular mechanism studiesDrug response profilingGenomic and transcriptomic analysis

Key Characteristics

Known genetic alterationsRelevant for colorectal cancer research
Generated on 6/16/2025

Basic Information

Database IDCVCL_1129
SpeciesHomo sapiens (Human)
Tissue SourceLymph node[UBERON:UBERON_0000029]

Donor Information

Age69
Age CategoryAdult
SexMale

Disease Information

DiseaseColon carcinoma
LineageBowel
SubtypeColon Adenocarcinoma
OncoTree CodeCOAD

DepMap Information

Source TypeDSMZ
Source IDACH-000350_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationNone reportedTP53---PubMed=19787792
MutationSimpleKRASp.Gly12Asp (c.35G>A)Unspecified-PubMed=29786757
MutationSimpleAPCp.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA)Heterozygous-from parent cell line WiDr

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
12
D13S317
10,13
D16S539
9
D18S51
11,14
D19S433
14
D21S11
27,29
D2S1338
24
D3S1358
15,18
D5S818
13,14
D7S820
8,12
D8S1179
12,13
FGA
25,27
Penta D
11,14
Penta E
10,16
TH01
9,9.3
TPOX
8
vWA
16,19
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

Pharmacoproteomic characterisation of human colon and rectal cancer.

Weichert W., Knapp S., Feller S.M., Kuster B.

Mol. Syst. Biol. 13:951-951(2017).

Genomic determinants of protein abundance variation in colorectal cancer cells.

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.

Cell Rep. 20:2201-2214(2017).

Multi-omics of 34 colorectal cancer cell lines -- a resource for biomedical studies.

Myklebost O., Skotheim R.I., Sveen A., Lothe R.A.

Mol. Cancer 16:116.1-116.16(2017).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.

Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.

Nat. Commun. 6:7002.1-7002.10(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.

Mariadason J.M., Sieber O.M.

Cancer Res. 74:3238-3247(2014).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

5-fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.

Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.

Br. J. Cancer 103:340-346(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells.

Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.

Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008).

Analysis of p53 mutations and their expression in 56 colorectal cancer cell lines.

Liu Y., Bodmer W.F.

Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).

Immunocytochemical analysis of cell lines derived from solid tumors.

Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.

J. Histochem. Cytochem. 49:1369-1378(2001).

APC mutations in sporadic colorectal tumors: a mutational 'hotspot' and interdependence of the 'two hits'.

Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.

Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000).

Web Resources